Allergan announces poster presentations at ASH Annual Scientific Meeting

Allergan plc announced its four poster presentations on hypertension management at the American Society of Hypertension (ASH) Annual Scientific Meeting

Data on the use of nebivolol and a fixed-dose combination (FDC) of nebivolol and valsartan to treat hypertension was shared at the meeting earlier this week.

"Nearly half of all hypertension patients in the U.S. have not achieved blood pressure control," Allergan Chief R&D Officer David Nicholson said. "Allergan is dedicated to continuing to develop and provide treatment options to help physicians and patients across various populations achieve control."

Nebivolol is approved for treatment of high blood pressure, or hypertension, under the name of BYSTOLIC. The nebivolol and valsartan FDC has been submitted to the U.S. Food and Drug Administration (FDA) and is awaiting approval.

The posters included the results of a study evaluating Hispanic patients' increased placebo response compared to other ethnic groups in nebivolol trials. A second poster showed the results of nebivolol on weight when treating hypertension patients.

The nebivolol and valsartan FDC study results were presented in two posters. The first showed the effects of the medication in reducing the blood pressure of patients suffering from Stage I or II hypertension. The second tested the medication's additivity versus other single pill combinations as a hypertension treatment.